A team of researchers has found a way to steer the output of large language models by manipulating specific concepts inside ...

Machine learning is an essential component of artificial intelligence. Whether it’s powering recommendation engines, fraud detection systems, self-driving cars, generative AI, or any of the countless ...

With countless applications and a combination of approachability and power, Python is one of the most popular programming languages for beginners and experts alike. We’ve compiled a list of 10 online ...

Found this to be true across different models: The agent starts a python REPL to inspect some object. For any subsequent commands they automatically enter the REPL and try to execute terminal commands ...

Thinking about learning Python? Google has a course for that, and it’s pretty popular. It’s a good way to get started with programming or to brush up on your skills. We’ll walk through what the google ...

Replimune received FDA acceptance for its RP1 BLA resubmission in advanced melanoma, with a PDUFA date set for April 2026. REPL stock surged nearly 100% on the news, but FDA acceptance only restarts ...

Trying to get your hands on the “Python Crash Course Free PDF” without breaking any rules? You’re not alone—lots of folks are looking for a legit way to ...

Python is one of the most popular programming languages in the world today, with millions of developers using it for web development, data science, machine learning, automation, and more. If you’ve ...

Python is an open-source general-purpose high-level interpreted programming language most popularly used for web development, and data science. And with Python skills being at an all-time request, ...

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...

The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...

On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...